Apothecon, et al.; Withdrawal of Approval of 103 New Drug Applications and 35 Abbreviated New Drug Applications; Correction
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on February 11, 2009. The document announced the withdrawal of approval of 103 new drug applications and 35 abbreviated new drug applications (ANDAs) from multiple applicants, withdrawn as of March 13, 2009. The document erroneously included ANDA 75-108. The correct ANDA is ANDA 76-108 for Amiodarone hydrochloride (HCl) injection, 50 milligrams (mg)/milliliter (mL), held by Hospira, Inc., 275 North Field Dr., Lake Forest, IL 60045-5046. This document corrects that error.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 242 (Tuesday, December 19, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 242 (Tuesday, December 19, 2023)]
[Notices]
[Pages 87787-87788]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-27859]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0026]
Apothecon, et al.; Withdrawal of Approval of 103 New Drug
Applications and 35 Abbreviated New Drug Applications; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
that appeared in the Federal Register on February 11, 2009. The
[[Page 87788]]
document announced the withdrawal of approval of 103 new drug
applications and 35 abbreviated new drug applications (ANDAs) from
multiple applicants, withdrawn as of March 13, 2009. The document
erroneously included ANDA 75-108. The correct ANDA is ANDA 76-108 for
Amiodarone hydrochloride (HCl) injection, 50 milligrams (mg)/milliliter
(mL), held by Hospira, Inc., 275 North Field Dr., Lake Forest, IL
60045-5046. This document corrects that error.
FOR FURTHER INFORMATION CONTACT: Kimberly Lehrfeld, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993-0002, 301-
796-3137, <a href="/cdn-cgi/l/email-protection#c388aaaea1a6b1afbaed8fa6abb1a5a6afa783a5a7a2edababb0eda4acb5"><span class="__cf_email__" data-cfemail="387351555a5d4a544116745d504a5e5d545c785e5c591650504b165f574e">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: In the Federal Register of February 11, 2009
(74 FR 6896), appearing on page 6900 in FR Doc. E9-2901, the following
correction is made:
On page 6900, in the table, in the first column, the Application
No. for the entry for Amiodarone HCL Injection, 50 mg/mL held by
Hospira Inc., 275 North Field Dr., Lake Forest, IL 60045-5046 is
corrected to ANDA 76-108.
Dated: December 14, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-27859 Filed 12-18-23; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.